ATLANTA–(BUSINESS WIRE)–CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, announced today the availability of a PD-L1 (programmed death-ligand 1) immunohistochemical (IHC) protein expression assay that can be used to potentially predict a patient’s response to several commercially available PD-1/PD-L1 inhibitor therapies.1 Presently, there are multiple PD-1/PD-L1 inhibitor …
Tag Archives: cancer diagnostics
July, 2016
December, 2015
-
3 December
MetaStat Presents Positive Data for its Breast Cancer Diagnostic Test
BOSTON–(BUSINESS WIRE)–MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company, today presented positive results from an analytical validation study demonstrating the analytical accuracy, reproducibility, and precision of its MetaSite Breast™ test at the Tumor Metastasis meeting of the American Association for Cancer Research (AACR) in Austin, Texas. The MetaSite Breast™ test predicts …
May, 2015
-
11 May
FDA Clears Roche’s KRAS Mutation Test for Colorectal Cancer Patients
Today, Roche announced that US health regulators have approved its diagnostic test for a certain gene mutation in patients with advanced colorectal cancer. The company said that the US Food and Drug Administration (FDA) approved the cobas KRAS Mutation Test for diagnostic use. The real-time polymerase chain reaction (PCR) test …
-
4 May
Biocept Launches its c-MET Biomarker
Molecular oncology diagnostics company, Biocept, Inc., is expanding its cancer diagnostic portfolio with the launch of a new liquid biopsy detection test. The company announced the launch of its c-MET amplification detection test utilizing a blood-based “liquid biopsy.” According to the company, the diagnostic assay can potentially help physicians identify …